54 results
PRE 14A
GLYC
GlycoMimetics Inc
22 Mar 24
Preliminary proxy
5:00pm
for that company’s worldwide commercialization and portfolio strategy across oncology, neurosciences and rare diseases. From February 2017 to February … officer, as well as her in-depth knowledge of operations and commercial strategy.
Mark Goldberg, M.D., age 69
Dr. Goldberg has served as a member
8-K
EX-99.1
GLYC
GlycoMimetics Inc
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
ability and ambition to deliver our development strategy and move closer to becoming a commercial stage company.”
Operational Highlights
Uproleselan
8-K
EX-99.1
GLYC
GlycoMimetics Inc
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am
of GlycoMimetics. “We continue to execute our broad development strategy for uproleselan while we explore potential benefit in AML patients of all
8-K
EX-99.1
uo6cc8
4 Oct 22
Regulation FD Disclosure
5:03pm
424B5
w5bzo2 otcx7p
28 Apr 22
Prospectus supplement for primary offering
5:01pm
8-K
EX-99.1
dsyy01mg60z
3 Mar 22
GlycoMimetics Reports Highlights and Financial Results
8:45am
8-K
EX-99.2
jyt03 c2yvrur
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am
8-K
kc4yr7
5 Aug 21
Glycomimetics Reports Highlights and Financial Results
8:01am